683 Capital Management LLC purchased a new stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 217,265 shares of the biotechnology company's stock, valued at approximately $539,000. 683 Capital Management LLC owned about 0.30% of Aclaris Therapeutics at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. ExodusPoint Capital Management LP bought a new position in Aclaris Therapeutics during the fourth quarter valued at $26,000. Invesco Ltd. purchased a new position in Aclaris Therapeutics during the 4th quarter valued at about $28,000. Commonwealth Equity Services LLC purchased a new position in Aclaris Therapeutics during the fourth quarter valued at approximately $36,000. Alpine Global Management LLC bought a new position in shares of Aclaris Therapeutics in the fourth quarter worth $38,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Aclaris Therapeutics in the 4th quarter worth about $82,000. 98.34% of the stock is currently owned by institutional investors.
Aclaris Therapeutics Trading Up 4.3 %
Shares of ACRS stock traded up $0.06 during midday trading on Friday, reaching $1.44. 668,869 shares of the stock were exchanged, compared to its average volume of 1,186,069. Aclaris Therapeutics, Inc. has a 1 year low of $0.95 and a 1 year high of $5.17. The firm has a market cap of $155.92 million, a PE ratio of -2.77 and a beta of 0.42. The company's 50 day moving average is $1.48 and its two-hundred day moving average is $2.25.
Analyst Ratings Changes
ACRS has been the topic of several research reports. StockNews.com cut shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 8th. Cantor Fitzgerald initiated coverage on Aclaris Therapeutics in a research note on Tuesday, March 18th. They issued an "overweight" rating on the stock. Finally, Scotiabank started coverage on shares of Aclaris Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target on the stock. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Aclaris Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $11.67.
Get Our Latest Research Report on ACRS
About Aclaris Therapeutics
(
Free Report)
Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
See Also
Before you consider Aclaris Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.
While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
